References
- Mayer R J, Davis R B, Schiffer C A, Berk D T, Powell B L, Schulman P, Omura G A, Moore J O, McIntyre O R, Frei E, For the Cancer and Leukemia Group B. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896
- Bishop J S, Matthews J T, Young G A, Szer J, Gilett A, Joshua D, Bradock K, Enno A, Wolf M M, Fox R, Cobcroft R, Hermann R, Van Der Weyden M, Lowenthal R M, Page F, Garson M, Juneja S. A randomized trial of high-dose cytarabine in acute myeloid leukemia. Blood 1996; 87: 1710
- Bloomfield C D, Lawrence D, Arthur D C, Berg D T, Schiffer C A, Mayer R J. Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood, 84: 10, Suppl. 1, 111a(abstr)
- Arlin Z, Case DC, Jr, Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 1990; 4: 177
- Alberts D S, Young L, Mason N, Salmon S E. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by peritoneal administration. Semin Oncol 1985; 12: 38, (Suppl. 4)
- Grant S, Arlin Z, Gewitz D, Feldman E. Effect of pharmacologically relevant concentration of mitoxantrone on the in vitro growth of leukemic blast progenitors. Leukemia 1991; 5: 336
- Bhaila K, Ibrado A M, Tourkina E, Tang C, Grant S, Bullock G, Huang Y, Ponnathpur V, Mahoney M E. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood 1993; 82: 3133
- Feldman E J, Alberts D, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng Y M, Baier M, Plezia P. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993; 11: 2002
- Dixon W J, Massey FJ, Jr. Introduction to Statistical Analysis (ed. 4). McGraw-Hill, New York 1983
- Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163
- Machin D, Campbell M J. Statistical Tables for the Design of Clinical Trials. Blackwell Scientific Publications, Oxford 1987
- Damon L E, Rugo H S, Ries C A, Linker C A. Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia. Leukemia Apr, 1994; 8(4)535–41
- Yates J W, Wallace H J, Ellison R R, Holland J F. Cytosine arabinoside (NSC-62878) and daunorubicin (NSC-83142) therapy in acute non-lymphocytic leukemia. Cancer Chemother Rep 1973; 57: 485
- Head D, Kopecky K J, Weick J, Files J C, Ryan D, Foucar K, Montiel M, Bickers J, Fishleder A, Miller M. Effect of aggressive daunomycin therapy on survival in acute promye-locytic leukemia. Blood 1995; 86: 1717
- Appelbaum F R, Dahlberg S, Thomas E D., Buckner C D, Cheever M A, Clift R A, Crowley J, Deeg H J, Fefer A, Green-Berg P D. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intem Med 1984; 101: 581
- Weick J K, Kopecky K J, Appelbaum F R, Head D R, Kingsbury L L, Balcerzak S P, Bickers J N, Hynes H E, Simon S R, Grever M. A randomized investigation of high-dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996; 88: 2841
- Cassileth P A, Lynch E, Hines J D, Oken M M, Mazza J J, Bennett J M, McGlave P B, Edelstein M, Harrington D PO, Con-Nell M J. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1995; 79: 1924